Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study

被引:35
|
作者
Gold, Michael S. [1 ]
Gidudu, Jane [2 ]
Erlewyn-Lajeunesse, Mich [3 ]
Law, Barbara [4 ]
机构
[1] Univ Adelaide, Discipline Paediat, Sch Paediat & Reprod Hlth, Adelaide, SA 5005, Australia
[2] Ctr Dis Control & Prevent, Atlanta, GA USA
[3] Southampton Univ Hosp NHS Trust, Southampton, Hants, England
[4] Publ Hlth Agcy Canada, Sci Sect, Immunizat & Resp Infect Div, Ottawa, ON, Canada
关键词
Brighton Collaboration anaphylaxis case definition; Checklists; Immunization safety; Case study; SAFETY DATA; GUIDELINES; COLLECTION;
D O I
10.1016/j.vaccine.2010.04.041
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Brighton Collaboration (BC) was established in 2000 with the aim of developing globally accepted standardized case definitions for adverse events following immunizations (AEFI) as well as guidelines for the collection, analysis and presentation of surveillance data. Some of the BC case definitions are complex and this may limit their application for use in post-marketing vaccine surveillance. Barriers to the application of the BC case definitions include an incomplete description of an adverse event and inconsistencies in reporter use of adverse event terms. We have taken the BC case definition for anaphylaxis and developed a clinical checklist and glossary of terms used in the case definition. It is anticipated that these resources can be used at a community level by AEFI reporters. If used, these resources could improve the quality of adverse event reports which would facilitate the application of the BC case definition at a regional and/or national level. (C) 2010 Published by Elsevier Ltd.
引用
收藏
页码:4487 / 4498
页数:12
相关论文
共 50 条
  • [41] Inadvertent inoculation as an adverse event following exposure to vaccinia virus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
    Wenger, Peter
    Oleske, James M.
    Kohl, Katrin S.
    Fisher, Margaret C.
    Brien, James H.
    Graham, Philip L.
    LaRussa, Philip S.
    Lipton, Susan
    Tierney, Bruce
    VACCINE, 2007, 25 (31) : 5754 - 5762
  • [42] Generalized vaccinia as an adverse event following exposure to vaccinia virus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
    Beigel, John
    Kohl, Katrin S.
    Brinley, Floyd
    Graham, Philip L.
    Khuri-Bulos, Najwa
    LaRussa, Philip S.
    Nell, Patricia
    Norton, Scott
    Stoltman, Gillian
    Tebaa, Amina
    Warschaw, Karen
    VACCINE, 2007, 25 (31) : 5745 - 5753
  • [43] Eczema vaccinatum as an adverse event following exposure to vaccinia virus: Case definition & guidelines of data collection, analysis, and presentation of immunization safety data
    Nell, Patricia
    Kohl, Katrin S.
    Graham, Philip L.
    LaRussa, Philip S.
    Marcy, S. Michael
    Fulginiti, Vincent A.
    Martin, Bryan
    Trolin, Ingrid
    Norton, Scott A.
    Neff, John M.
    VACCINE, 2007, 25 (31) : 5725 - 5734
  • [44] Genetic Risk Factors for Neurological Disorders in Children with Adverse Events following Immunization: A Descriptive Study of a Polish Case Series
    Charzewska, Agnieszka
    Terczynska, Iwona
    Lipiec, Agata
    Mazurczak, Tomasz
    Gorka-Skoczylas, Paulina
    Szlendak, Roza
    Kanabus, Karolina
    Tataj, Renata
    Dawidziuk, Mateusz
    Wojtas, Bartosz
    Gielniewski, Bartlomiej
    Bal, Jerzy
    Stawicka, Elzbieta
    Hoffman-Zacharska, Dorota
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [45] Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's adverse event reporting system and review of case reports in the literature
    Raisch, Dennis W.
    Garg, Vishvas
    Arabyat, Rasha
    Shen, Xian
    Edwards, Beatrice J.
    Miller, Frank H.
    McKoy, June M.
    Nardone, Beatrice
    West, Dennis P.
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (01) : 15 - 23
  • [46] Phenotypic spectrum of serious cutaneous-only adverse event following immunization with COVID-19 vaccines: a multicentre case series and literature review
    Balogun, M.
    Millette, D.
    Yip, V.
    Chan, S. A.
    Lee, P.
    Gamal, N.
    Hashim, N.
    Phillips, D.
    Walsh, M.
    Trehan, P.
    Hanna-Bashara, L.
    Abdullah, A.
    Wernham, A.
    Tso, S.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (03) : 614 - 616
  • [47] The futility of adverse drug event reporting systems for monitoring known safety issues: A case study of myocardial infarction with rofecoxib and other drugs
    Haguinet, Francois
    Bate, Andrew
    Stegmann, Jens-Ulrich
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
  • [48] Estimating the extent of adverse event reporting to the US food and drug administration: A case-study of the statin-associated rhabdomyolysis data
    McAdams, Mara
    Staffa, Judy
    Dal Pan, Gerald
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S70 - S70
  • [49] Can participatory water management improve residents' subjective life quality? A case study from China
    Pan, Hulin
    Guo, Min
    WATER SUPPLY, 2019, 19 (05) : 1547 - 1554
  • [50] Can mentorship improve laboratory quality? A case study from influenza diagnostic laboratories in Southeast Europe
    Lauren Polansky
    Stephanie Chester
    Melissa Warren
    Tricia Aden
    Pamela Kennedy
    Stacey Spivey-Blackford
    Ann Moen
    BMC Health Services Research, 19